ES2625823T3 - Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo - Google Patents

Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Download PDF

Info

Publication number
ES2625823T3
ES2625823T3 ES12170984T ES12170984T ES2625823T3 ES 2625823 T3 ES2625823 T3 ES 2625823T3 ES 12170984 T ES12170984 T ES 12170984T ES 12170984 T ES12170984 T ES 12170984T ES 2625823 T3 ES2625823 T3 ES 2625823T3
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
seq
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12170984T
Other languages
English (en)
Inventor
Yuji Yamazaki
Itaru Urakawa
Hitoshi Yoshida
Yukiko Aono
Takeyoshi Yamashita
Takashi Shimada
Hisashi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2625823(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2625823T3 publication Critical patent/ES2625823T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Anticuerpo frente a FGF23 humano o un fragmento funcional de dicho anticuerpo frente a FGF23 humano, a) en el que el anticuerpo frente a FGF23 humano o el fragmento funcional de dicho anticuerpo comprende una región variable de cadena pesada que tiene una región determinante de la complementariedad (CDR) 1 mostrada por la secuencia de aminoácidos de SEC ID Nº:40, CDR2 mostrada por la secuencia de aminoácidos de SEC ID Nº:41 y CDR3 mostrada por la secuencia de aminoácidos de SEC ID Nº:42, y una región variable de cadena ligera que tiene una región determinante de la complementariedad (CDR) 1 mostrada por la secuencia de aminoácidos de SEC ID Nº:43, CDR2 mostrada por la secuencia de aminoácidos de SEC ID Nº:44 y CDR3 mostrada por la secuencia de aminoácidos de SEC ID Nº:45, o b) en el que el anticuerpo frente a FGF23 humano se produce mediante hibridoma FERM BP-10772, o c) anticuerpo o fragmento que comprende la misma secuencia de aminoácidos que una región variable de cadena pesada y una región variable de cadena ligera de un anticuerpo producido mediante hibridoma FERM BP-10772.
ES12170984T 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Active ES2625823T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14

Publications (1)

Publication Number Publication Date
ES2625823T3 true ES2625823T3 (es) 2017-07-20

Family

ID=39690189

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES08711707T Active ES2530670T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES08711707T Active ES2530670T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Country Status (23)

Country Link
US (4) US7883705B2 (es)
EP (3) EP3181691B1 (es)
JP (1) JP4800396B2 (es)
KR (1) KR101462291B1 (es)
CN (2) CN101652476B (es)
AU (1) AU2008215346B2 (es)
CA (1) CA2677782C (es)
CY (3) CY1118835T1 (es)
DK (3) DK2502996T3 (es)
ES (3) ES2625823T3 (es)
FR (1) FR18C1032I2 (es)
HK (2) HK1140228A1 (es)
HR (2) HRP20170548T1 (es)
HU (3) HUE050517T2 (es)
LT (3) LT2502996T (es)
LU (2) LUC00081I2 (es)
NL (1) NL300945I2 (es)
NO (1) NO2018025I1 (es)
PL (3) PL3181691T3 (es)
PT (3) PT2128253E (es)
SI (2) SI2502996T1 (es)
TW (1) TWI422593B (es)
WO (1) WO2008099969A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100387713C (zh) * 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
EP1466925B1 (en) * 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antibodies against fibroblast growth factor 23
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
AU2015275128C1 (en) * 2014-06-09 2020-02-13 Kyowa Kirin Co., Ltd. The effective and efficient control of serum phosphate for optimal bone formation
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
JP7023932B2 (ja) 2017-03-30 2022-02-22 シスメックス株式会社 抗ＡｐｏＡ１抗体
BR112021019337A2 (pt) * 2019-03-29 2021-12-07 Atarga Llc Anticorpo anti-fgf23
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (es) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
DE69935220T2 (de) 1998-05-18 2007-11-15 University College London Von menschlichem tumor stammendes polypeptidhormon phosphatonin
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
EP1246843A1 (en) 2000-01-05 2002-10-09 ZymoGenetics, Inc. Novel fgf homolog zfgf12
JP2003523190A (ja) 2000-02-14 2003-08-05 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU3976701A (en) 2000-02-15 2001-08-27 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20030105302A1 (en) 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
EP1261638A2 (en) 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
CN100387713C (zh) 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
CA2443719A1 (en) 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
EP1466925B1 (en) 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antibodies against fibroblast growth factor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JPWO2004083425A1 (ja) * 2003-03-17 2006-06-22 麒麟麦酒株式会社 歯周病治療剤
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
CN102942631B (zh) * 2004-08-05 2015-03-25 健泰科生物技术公司 人源化抗c-met拮抗剂
EP1801208A4 (en) * 2004-09-06 2009-04-01 Kirin Pharma Kk ANTI-A33 ANTIBODIES
JPWO2006078072A1 (ja) 2005-01-21 2008-06-19 キリンファーマ株式会社 キメラ非ヒト動物およびその使用
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
WO2008092019A1 (en) * 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
TWI422593B (zh) 2014-01-11
JPWO2008099969A1 (ja) 2010-05-27
US10202446B2 (en) 2019-02-12
PL3181691T3 (pl) 2020-11-02
CN101652476A (zh) 2010-02-17
ES2530670T3 (es) 2015-03-04
NL300945I1 (en) 2018-08-15
CA2677782C (en) 2016-07-26
CA2677782A1 (en) 2008-08-21
EP2128253A4 (en) 2010-03-10
WO2008099969A1 (ja) 2008-08-21
EP2502996B1 (en) 2017-03-29
AU2008215346B2 (en) 2013-01-10
EP3181691B1 (en) 2020-07-15
HUE031728T2 (en) 2017-07-28
HRP20170548T1 (hr) 2017-08-25
PT2128253E (pt) 2015-02-04
US20110182913A1 (en) 2011-07-28
DK3181691T3 (da) 2020-08-17
US20160159895A1 (en) 2016-06-09
EP2128253B1 (en) 2014-12-03
AU2008215346A1 (en) 2008-08-21
KR20090114452A (ko) 2009-11-03
CY2018021I2 (el) 2019-07-10
CN102702355A (zh) 2012-10-03
PT3181691T (pt) 2020-08-26
EP2128253A1 (en) 2009-12-02
US20090148461A1 (en) 2009-06-11
US9290569B2 (en) 2016-03-22
CY2018021I1 (el) 2019-07-10
CY1123240T1 (el) 2021-10-29
EP2502996A3 (en) 2013-04-10
HRP20201266T1 (hr) 2021-02-05
NL300945I2 (en) 2020-05-13
NO2018025I1 (no) 2018-08-09
CN101652476B (zh) 2012-07-04
CY1118835T1 (el) 2018-01-10
LUC00081I2 (es) 2018-10-01
EP2502996A2 (en) 2012-09-26
JP4800396B2 (ja) 2011-10-26
LT2502996T (lt) 2017-06-26
US20190106485A1 (en) 2019-04-11
FR18C1032I2 (fr) 2019-08-09
PL2502996T3 (pl) 2017-07-31
DK2502996T3 (en) 2017-05-08
KR101462291B1 (ko) 2014-11-14
HUS1800034I1 (hu) 2018-09-28
LTPA2018508I1 (lt) 2018-09-10
LT3181691T (lt) 2020-08-25
DK2128253T3 (en) 2015-01-05
PT2502996T (pt) 2017-05-10
PL2128253T3 (pl) 2015-04-30
ES2811318T3 (es) 2021-03-11
TW200902549A (en) 2009-01-16
US7883705B2 (en) 2011-02-08
SI2502996T1 (sl) 2017-08-31
LUC00082I2 (es) 2018-10-01
LTC2502996I2 (lt) 2019-05-10
HUE050517T2 (hu) 2020-12-28
FR18C1032I1 (es) 2018-08-31
EP3181691A1 (en) 2017-06-21
SI3181691T1 (sl) 2020-09-30
HK1172917A1 (en) 2013-05-03
HK1140228A1 (en) 2010-10-08
CN102702355B (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
ES2625823T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
PE20141435A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
UY30260A1 (es) Anticuerpos dirigidos contra upar y usos de los mismos
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
TW200716182A (en) Antibodies directed to CD20 and uses thereof
AR052889A1 (es) Anticuerpos contra interleuquina-1 beta
RS53819B1 (en) ANTI-ACTIVIN ANTIBODIES AND THEIR APPLICATIONS
UY29288A1 (es) Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos
RS53258B (en) HUMAN ANTIBODIES AGAINST HEPATITIS C (HCV) VIRUS AND USE
RS52860B (en) ANTI-ILT7 ANTITELO
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
NZ595235A (en) Compositions and methods for increasing muscle growth
ES2570153T3 (es) Anticuerpos anti-C5aR con propiedades mejoradas
RS53924B1 (en) NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof